Summary
Fifteen patients with advanced metastatic adenocarcinomas were treated in a phase-I study with continuous intravenous 24h infusion of recombinant tumor necrosis factor α (TNF-α) in order to determine the maximum tolerated dose (MTD) and associated side-effects. Patients received 40–400 μg/m2 TNF-α once (arm A) or twice (arm B) weekly for a scheduled treatment period of 2 months. The observed systemic side-effects resembled those reported for interferons and included fever, chills, fatigue, headaches, myalgias, thrombocytopenia, prostration, and malaise. Dose-limiting toxicities, resulting in a median MTD of 200 μg/m2 for 24h, were fever, chills, fatique, myalgias, and thrombocytopenia. Out of 15 patients, 11 showed tumor progression, and 3 sustained in no change for over 2 months of treatment. A minor response was seen in 1 patient with a colorectal carcinoma and liver metastases. To reduce side-effects, patients were treated either with paracetamol or indomethacin. Higher MTDs were observed in patients treated with indomethacin. No detectable plasma TNF-α levels or TNF antibodies were measured under therapy (plasma TNF-α<20 pg/ml). We conclude that TNF-α appears to have some antineoplastic activity in patients with adenocarcinomas since 4 patients remained in no change or showed a minor response.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aggarwal BB, Henzel WJ, Moffat B, Kohr WJ, Harkins RN (1985a) Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem 260:2334–2344
Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN (1985b) Human tumor necrosis factor. J Biol Chem 260:2345–2354
Andus T, Heinrich PC, Bauer J, Tran-Thi T-A, Decker K, Männel DN, Northoff H (1987) discrimination of hepatocyte stimulating activity from human recombinant tumor necrosis factor α. Eur J Immunol 17:1193–1197
Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316:379–385
Beutler B, Greenwald D, Hulmes JD, Chang M, Pan Y-CE, Mathison J, Uleritch R, Cerami A (1985) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552–554
Blick M, Sherwin SA, Rosenblum M, Gutterman J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986–2989
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666–3670
Haranaka KH, Satomji N, Sakurai A (1984) Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and hetero-transplanted human tumors in nude mice. Int J Cancer 34:263–267
Kist A, Ho AD, Räth U, Wiedenmann B, Bauer A, Schlick E, Kirchner H, Männel DN (1988) Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Blood 72:344–348
Miller AB, Hoogstraten B, Staquet M (1981) Reporting results of cancer treatment. Cancer 47:207–214
Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312:721–729
Quesada J, Swanson DA, Trindade A, Gutterman JU (1983) Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 43:940–947
Sassa S, Kawakami M, Cerami A (1983) Inhibition of the growth and differentiation of erythroid precursor cells by an endotoxin-induced mediator from peritoneal macrophages. Proc Natl Acad Sci USA 80:1717–1720
Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei III E, Kufe DW (1988) Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients. Phase I toxicity and effects on lipid metabolism. J Clin Oncol 6:344–350
Shirai T, Yamaguchi M, Ito H, Todd CW, Wallace RB (1985) Cloning and expression in Escherichia coli of the gene for human tumor necrosis factor. Nature 313:803–806
Trump DL, Grem JL, Alberti D, Simon K, Brown R, Rosenzweig B, Remick SC, Willson JKV (1987) A clinical trial of recombinant tumor necrosis factor (rTNF) administered three times weekly. Proc Am Assoc Cancer Res 28:401
Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, van Arsdell JN, Yamamoto R, Mark DF (1985) Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228:149–154
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wiedenmann, B., Reichardt, P., Räth, U. et al. Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 115, 189–192 (1989). https://doi.org/10.1007/BF00397922
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00397922